Azitra (AZTR) news
Recent news
Azitra, Inc. regains compliance with NYSE American continued listing standards
AInvest Wire · Aug 21, 2026Azitra - to pause further enrollment in ATR-12 trial to redirect funds to ATR-COSF
Azitra Inc. has announced a strategic shift in its clinical development priorities, pausing further enrollment in its ATR-12 trial to redirect resources toward its ATR-COSF program . The decision follows a comprehensive review of the company’s research portfolio and an assessment of the potential…
AInvest Wire · Jun 17, 2026Azitra, Inc. CEO issues letter to shareholders detailing strategic reorientation initiatives and outlook for 2026 and beyond
AInvest Wire · Jun 17, 2026ImportantAzitra announces 1-for-30 reverse stock split
Azitra announces 1-for-30 reverse stock split Azitra, Inc. (AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, announced its intention to execute a 1-for-30 reverse stock split effective July 1, 2024 [1]. This decision comes following a stockholders meeting on…
AInvest Wire · Jun 27, 2024ImportantAzitra Shares Rise 17% After New U.S. Patent
Azitra Shares Rise 17% After New U.S. Patent Azitra, a biotechnology company, recently announced that it has been granted a new patent in the United States. This new patent covers a novel technology that the company has developed for the treatment of various skin conditions, including acne and…
AInvest Wire · Jan 16, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.